Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ipsen
Ipsen
Relocating its US HQ to Boston, French pharma Ipsen to add 250 jobs
Endpoints
Thu, 06/7/18 - 10:50 pm
biotech
Boston
Kendall Square
Ipsen
hirings
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Thu, 05/17/18 - 09:42 am
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Ipsen focuses on oncology to keep growing
GoInPharma
Mon, 09/18/17 - 09:24 am
Ipsen
oncology
Xermelo
kidney cancer
Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug
Mass Device
Tue, 07/4/17 - 11:05 pm
Ipsen
gastroenteropancreatic neuroendocrine tumor
Somatuline
Sanofi Sells 5 Over-the-Counter Drugs for $88M
Investopedia
Tue, 02/14/17 - 09:20 am
Sanofi
OTC
M&A
Ipsen
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal
Yahoo/Reuters
Mon, 01/9/17 - 09:54 am
Ipsen
France
Merrimack Pharmaceuticals
pancreatic cancer
Onivyde
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Sun, 06/5/16 - 11:59 am
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Ipsen to Step Up Deal-Making, Scout for New Cancer Products
Bloomberg
Tue, 01/19/16 - 04:27 pm
Ipsen
M&A
oncology
Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push
Fierce Pharma Marketing
Wed, 11/26/14 - 11:50 am
Ipsen
Somatuline
hirings
drug launches
Nestle’s Galderma Deepens Ipsen Alliance for Wrinkle Smoother
Bloomberg
Fri, 07/11/14 - 08:32 am
Nestle
Galderma
Ipsen
Dysport
Azzalure
China Drug Probe Leads to Tougher Market, Ipsen CEO Says
Bloomberg
Fri, 08/30/13 - 09:28 am
China
Ipsen
Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech
Fierce Biotech
Thu, 01/24/13 - 11:32 am
Baxter International
Ipsen
hemophilia
Roche Said to Return Diabetes Drug Rights to Ipsen
Bloomberg
Tue, 02/1/11 - 08:25 am
Ipsen
Roche
diabetes
taspoglutide
The Top 10 Phase III Failures of 2010
Fierce Biotech
Fri, 10/22/10 - 11:36 am
clinical trials
dimebon
Medivation
Pfizer
ocrelizumab
Roche
rheumatoid arthritis
taspoglutide
diabetes
Ipsen
semagacestat
Eli Lilly
ASA404
Antisoma
Novartis
Novelos Therapeutics
AstraZeneca
zibotentan
vicriviroc
Merck
Recentin
Vical
Sanofi
Roche’s Taspoglutide for Diabetes Meets Goal, Ipsen Says
Bloomberg
Thu, 04/29/10 - 07:15 am
Ipsen
Roche
diabetes
taspoglutide
FDA Warns Researcher For Promoting A Drug
Pharmalot
Wed, 01/27/10 - 10:59 am
FDA
Reloxin
Ipsen
Dysport
Ipsen Buys Inspiration Stake in Hemophilia Alliance
Bloomberg
Thu, 01/21/10 - 07:47 am
hemophilia
Ipsen
Inspiration
M&A
Ipsen, Roche’s Taspoglutide Matches Sanofi’s Lantus
Bloomberg
Thu, 12/17/09 - 08:57 am
Lantus
diabetes
Ipsen
Roche
taspoglutide
Roche's New Diabetes Drug Works Better Than Byetta
WSJ Online
Thu, 10/29/09 - 09:05 am
Byetta
diabetes
Roche
Ipsen
taspoglutide
Ipsen Afflicted by Too Many Drugs, Bucks Trend Infecting Others
Bloomberg
Mon, 07/6/09 - 05:12 am
Ipsen
Allergan
Botox
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »